BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 29274754)

  • 41. Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study.
    Zanella L; Zoppellaro G; Marigo L; Denas G; Padayattil Jose S; Pengo V
    Cardiovasc Ther; 2018 Oct; 36(5):e12458. PubMed ID: 30007110
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Validation of Bleeding Risk Prediction Scores for Patients With Major Bleeding on Direct Oral Anticoagulants.
    Tchen S; Ryba N; Patel V; Cavanaugh J; Sullivan JB
    Ann Pharmacother; 2020 Dec; 54(12):1175-1184. PubMed ID: 32517484
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
    Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
    Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.
    Serna MJ; Rivera-Caravaca JM; Gonzalez-Conejero R; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Roldán V; Marín F
    Eur J Clin Invest; 2018 Jun; 48(6):e12929. PubMed ID: 29577257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HAS-BLED score as a predictor of bleeding complications from catheter ablation of atrial fibrillation: A subanalysis of the Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registries.
    Inoue K; Hirao K; Aonuma K; Kumagai K; Kimura M; Miyauchi Y; Tsushima E; Okumura K;
    J Cardiol; 2020 Jan; 75(1):82-89. PubMed ID: 31327705
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation.
    Chao TF; Chan YH; Chiang CE; Tuan TC; Liao JN; Chen TJ; Lip GYH; Chen SA
    Clin Res Cardiol; 2022 Jan; 111(1):23-33. PubMed ID: 33704551
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Usefulness of the CHA
    Jaakkola S; Kiviniemi TO; Nuotio I; Hartikainen J; Mustonen P; Palomäki A; Jaakkola J; Ylitalo A; Hartikainen P; Airaksinen KEJ
    Am J Cardiol; 2018 May; 121(10):1182-1186. PubMed ID: 29526276
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation.
    O'Brien EC; Holmes DN; Thomas LE; Fonarow GC; Allen LA; Gersh BJ; Kowey PR; Singer DE; Ezekowitz MD; Naccarelli GV; Ansell JE; Chan PS; Mahaffey KW; Go AS; Freeman JV; Reiffel JA; Peterson ED; Piccini JP; Hylek EM
    Circulation; 2018 Aug; 138(9):889-897. PubMed ID: 29678813
    [TBL] [Abstract][Full Text] [Related]  

  • 49. External Validation of the ORBIT Bleeding Score and the HAS-BLED Score in Nonvalvular Atrial Fibrillation Patients Using Direct Oral Anticoagulants (Asian Data from the DIRECT Registry).
    Mori N; Sotomi Y; Hirata A; Hirayama A; Sakata Y; Higuchi Y
    Am J Cardiol; 2019 Oct; 124(7):1044-1048. PubMed ID: 31353002
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.
    Proietti M; Hijazi Z; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Lane DA; Oldgren J; Roldan V; Yusuf S; Wallentin L;
    J Intern Med; 2018 Mar; 283(3):282-292. PubMed ID: 29044861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Performance of bleeding risk-prediction scores in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Kiviniemi T; Puurunen M; Schlitt A; Rubboli A; Karjalainen P; Vikman S; Niemelä M; Lahtela H; Lip GY; Airaksinen KE
    Am J Cardiol; 2014 Jun; 113(12):1995-2001. PubMed ID: 24793675
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA
    Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Marín F; Lip GYH
    Am Heart J; 2018 Mar; 197():27-34. PubMed ID: 29447781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure.
    Savarese G; Sartipy U; Friberg L; Dahlström U; Lund LH
    Heart; 2018 Jul; 104(13):1093-1100. PubMed ID: 29371374
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis.
    Zhu W; He W; Guo L; Wang X; Hong K
    Clin Cardiol; 2015 Sep; 38(9):555-61. PubMed ID: 26418409
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Predictive value of four score systems on the bleeding risk in atrial fibrillation patients treated with dabigatran].
    Ding CC; Zhan BM; Zhou W; Li MH; Hu LH; Bao HH; Cheng XS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Sep; 48(9):748-752. PubMed ID: 32957757
    [No Abstract]   [Full Text] [Related]  

  • 56. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
    Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Held C; Hylek EM; Lopes RD; Siegbahn A; Yusuf S; Granger CB; Wallentin L;
    Lancet; 2016 Jun; 387(10035):2302-2311. PubMed ID: 27056738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation.
    Lip GY
    Am J Med; 2011 Feb; 124(2):111-4. PubMed ID: 20887966
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients.
    Song HY; Son KB; Shin JY; Bae S
    Int J Clin Pharm; 2019 Dec; 41(6):1434-1441. PubMed ID: 31522377
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial.
    Guo Y; Lane DA; Chen Y; Lip GYH;
    Am J Med; 2020 Oct; 133(10):1195-1202.e2. PubMed ID: 32289310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.
    Steinberg BA; Gao H; Shrader P; Pieper K; Thomas L; Camm AJ; Ezekowitz MD; Fonarow GC; Gersh BJ; Goldhaber S; Haas S; Hacke W; Kowey PR; Ansell J; Mahaffey KW; Naccarelli G; Reiffel JA; Turpie A; Verheugt F; Piccini JP; Kakkar A; Peterson ED; Fox KAA; ;
    Am Heart J; 2017 Dec; 194():132-140. PubMed ID: 29223431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.